お見積

サンプルお申込み

お問い合わせ

今すぐ購入

※ご注文方法：お問い合わせフォームまたはメールにてご連絡ください。
支払方法：「銀行振込」の場合， 注文の確認後、ご指定のメールアドレスに電子版の請求書をお送りいたしますので、電子版の請求書の記載事項に従って送金操作を行ってください。
※納期：原則として、受注後2～4営業日以内に発送いたします。 但し、日本語版が必要な場合は、受注後8～10営業日となります。 お客様のニーズに合わせて、事前にご注文のスケジュールをお立てください。

本報告書はオリゴヌクレオチド治療薬市場規模の世界市場の概要を紹介します。2019~2023年の歴史的な市場収益データ、2024年の予想、および2030年までのCAGRの予測を含む世界市場動向の分析。レポートはオリゴヌクレオチド治療薬の主要メーカーを詳細に分析し、地域別・国別の収益プロフィールを明らかにしています。 本レポートでは特に、主要地域/国別のセグメントとサブセグメントについて、将来の市場ポテンシャルの探索と予測に焦点を当てています。 複数の地域にわたる包括的なデータと市場価値分析により、読者は包括的かつ詳細な市場洞察を得ることができます。

世界のオリゴヌクレオチド治療薬市場の主な参加者である企業概要、収益、粗利益率、ポートフォリオ、地理的位置、重要な発展について、次のパラメータに基づいて説明します。レポートはオリゴヌクレオチド治療薬のメーカー、地域、種類と端末業界の角度から世界と主要地域の市場現状と将来性を研究した、このレポートでは、世界と主要地域のトップメーカーを分析し、タイプとアプリケーション/端末業界別にオリゴヌクレオチド治療薬市場を分類しています。本研究に含まれる主な企業は：Sarepta Therapeutics、Ionis Pharmaceuticals、Alnylam、Biogen、Nippon Shinyaku、Sobi、Novartis、BioNTech、Pfizer、Moderna Therapeutics、Jazz Pharmaceuticals、CureVac、Regulus Therapeutics、ProQR、Secarna、MiNA Therapeutics、Sylentis、Arrowhead、Silence Therapeutics、Dicerna

地域別市場区分、地域別分析は以下の通り：
    アメリカとカナダ
    中国
    アジア
    ヨーロッパ
    中東、アフリカ、ラテンアメリカ

タイプ別市場セグメント：
    Antisense Oligonucleotides (ASO)
    siRNA
    mRNA

用途別の市場セグメント：
    Neuromuscular Diseases
    hATTR
    COVID-19
    Other

本レポートの詳細内容
世界のオリゴヌクレオチド治療薬市場の現状と将来について、グローバルの主要地域を中心に包括的に分析しています。 当レポートでは、多角的な分析を通じて、市場プレイヤー、地域分布、オリゴヌクレオチド治療薬タイプ、最終用途アプリケーションなどの主要分野を掘り下げ、読者に包括的な市場洞察を提供しています。 レポートは主要企業のオリゴヌクレオチド治療薬収益、市場シェア、業界ランキング、2019年から2024年までのデータに焦点を当てています。世界のオリゴヌクレオチド治療薬市場における主要なステークホルダーの特定、最近の動向とセグメント収益に基づいて競争状況と市場ポジショニングの分析。また、当レポートでは、世界市場の主要プレイヤーを特定し、プロファイルを作成するとともに、オリゴヌクレオチド治療薬市場を綿密に分類・応用することで、読者が市場構造とダイナミクスをより正確に把握できるようにし、十分な情報に基づいた意思決定と戦略立案に強力なサポートを提供しています。

オリゴヌクレオチド治療薬のレポートは2019年から2030年までのタイプ別およびアプリケーション別、収益、成長率別のセグメントデータを分析します。収益、予測成長傾向、アプリケーション、およびエンドユーザー業界の市場規模を評価および予測します。

章の概要
第1章：オリゴヌクレオチド治療薬のレポートの報告範囲、各セグメントの市場規模、将来の開発可能性などを含む、さまざまな市場セグメント（製品タイプ、用途など）のエグゼクティブサマリーを紹介します。市場の現状と、短期から中期、および長期的な進化の可能性をハイレベルに見ることができます。（2019～2030）
第2章：オリゴヌクレオチド治療薬の世界及び地域レベルでの売上高。各地域とその主要国の市場規模と発展の可能性を定量的に分析し、世界各国の市場発展、今後の発展展望、市場空間、生産能力などを紹介する。また、市場ダイナミクス、市場の最新動向、市場の推進要因と制限要因、業界企業が直面する課題とリスク、業界の関連政策の分析などを紹介しています。（2019～2030）
第3章オリゴヌクレオチド治療薬企業の競争状況、収益、市場シェアと業界ランキング、最新の開発計画、合併・買収情報などの詳細分析。（2019～2030）
第4章：各市場セグメントの収益と開発の可能性をカバーし、種類別のさまざまな市場セグメントの分析を提供し、読者がさまざまな市場セグメントでブルーオーシャン市場を見つけるのに役立ちます。（2019～2024）
第5章：オリゴヌクレオチド治療薬の各市場セグメントの収益と開発の可能性をカバーするアプリケーション別のさまざまな市場セグメントの分析を提供し、読者がさまざまな下流市場でブルーオーシャン市場を見つけるのに役立ちます。（2019～2030）
第6章：北米（米国、カナダ）のタイプ別、アプリケーション別、国別、各セグメントの収益。（2019～2030）
第7章：ヨーロッパのタイプ別、アプリケーション別、国別、各セグメントの収益。（2019～2030）
第8章：中国の種類別、および用途別、各セグメントの収益。（2019～2030）
第9章アジア（中国を除く）の種類別、用途別、地域別、セグメントごとの収益。（2019～2030）
第10章：中東、アフリカ、ラテンアメリカの種類別、アプリケーション別、国別、各セグメントの収益。（2019～2030）
第11章：オリゴヌクレオチド治療薬の主要企業の概要を提供し、製品の説明と仕様、オリゴヌクレオチド治療薬の収益、粗利益率、最近の展開など、市場の主要企業の基本状況を詳細に紹介します。（2019～2024）
第12章：アナリストの見解/結論

Oligonucleotide therapeutics are a class of precision medicines composed of short DNA or RNA sequences designed to specifically target and modulate the expression of genes involved in disease processes. These therapies can act by silencing, inhibiting, or correcting genetic abnormalities at the molecular level, offering a highly targeted approach to treat various conditions such as genetic disorders, cancers, and viral infections. Oligonucleotide therapeutics include antisense oligonucleotides, small interfering RNA (siRNA), and aptamers, and they represent a promising area of drug development due to their ability to address previously untreatable diseases.
The global Oligonucleotide Therapeutics market is projected to grow from US$ 7536 million in 2024 to US$ 9377 million by 2030, at a Compound Annual Growth Rate (CAGR) of 3.7% during the forecast period.
Key driver of the oligonucleotide therapeutics market is the growing prevalence of genetic and rare diseases that require precise and targeted treatment options. Advances in genomics and personalized medicine have fueled interest in oligonucleotide therapies, which can directly modulate gene expression and offer solutions for conditions that were previously difficult to treat. The success of approved oligonucleotide drugs, such as antisense oligonucleotides and siRNA therapies, has increased confidence in this field, leading to more investments and research in developing novel treatments for a wide range of diseases, including cancers and neurological disorders.
One significant challenge in the oligonucleotide therapeutics market is the complexity of delivering these molecules effectively to target cells or tissues. Oligonucleotides are large, negatively charged molecules that face hurdles in stability, bioavailability, and efficient cellular uptake. Developing delivery systems that can ensure targeted and sustained delivery while minimizing immune responses or off-target effects remains a critical challenge. Additionally, the high costs associated with research, development, and manufacturing of oligonucleotide-based drugs pose financial challenges, limiting accessibility and widespread adoption, especially in resource-constrained healthcare settings.
Europe is the largest consumption place, with a consumption market share nearly 44.61% in 2023. Following Europe, North Americas is the second largest consumption place with the consumption market share of 34.9%. The global key companies of oligonucleotide therapeutics include Pfizer, Moderna Therapeutics, BioNTech, Biogen, Alnylam, Sarepta Therapeutics, Jazz Pharmaceuticals, Nippon Shinyaku, Novartis, Sobi, Ionis Pharmaceuticals, etc. In 2023, the global top five players had a share approximately 97.87% in terms of revenue.
Report Includes
This report presents an overview of global market for Oligonucleotide Therapeutics market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Oligonucleotide Therapeutics, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Oligonucleotide Therapeutics, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Oligonucleotide Therapeutics revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Oligonucleotide Therapeutics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Oligonucleotide Therapeutics revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Sarepta Therapeutics, Ionis Pharmaceuticals, Alnylam, Biogen, Nippon Shinyaku, Sobi, Novartis, BioNTech, Pfizer, Moderna Therapeutics, etc.

Market Segmentation
By Company
    Sarepta Therapeutics
    Ionis Pharmaceuticals
    Alnylam
    Biogen
    Nippon Shinyaku
    Sobi
    Novartis
    BioNTech
    Pfizer
    Moderna Therapeutics
    Jazz Pharmaceuticals
    CureVac
    Regulus Therapeutics
    ProQR
    Secarna
    MiNA Therapeutics
    Sylentis
    Arrowhead
    Silence Therapeutics
    Dicerna

Segment by Type
    Antisense Oligonucleotides (ASO)
    siRNA
    mRNA

Segment by Application
    Neuromuscular Diseases
    hATTR
    COVID-19
    Other

By Region
    North America
        United States
        Canada
    Asia-Pacific
        China
        Japan
        South Korea
        Southeast Asia
        India
        Australia
        Rest of Asia
    Europe
        Germany
        France
        U.K.
        Italy
        Russia
        Nordic Countries
        Rest of Europe
    Latin America
        Mexico
        Brazil
        Rest of South America
    Middle East & Africa
        Turkey
        Saudi Arabia
        UAE
        Rest of MEA

Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Oligonucleotide Therapeutics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Oligonucleotide Therapeutics companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Oligonucleotide Therapeutics revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions

List of Tables
 Table 1. Global Oligonucleotide Therapeutics Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
 Table 2. Key Players of Antisense Oligonucleotides (ASO)
 Table 3. Key Players of siRNA
 Table 4. Key Players of mRNA
 Table 5. Global Oligonucleotide Therapeutics Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
 Table 6. Global Oligonucleotide Therapeutics Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
 Table 7. Global Oligonucleotide Therapeutics Market Size by Region (2019-2024) & (US$ Million)
 Table 8. Global Oligonucleotide Therapeutics Market Share by Region (2019-2024)
 Table 9. Global Oligonucleotide Therapeutics Forecasted Market Size by Region (2025-2030) & (US$ Million)
 Table 10. Global Oligonucleotide Therapeutics Market Share by Region (2025-2030)
 Table 11. Oligonucleotide Therapeutics Market Trends
 Table 12. Oligonucleotide Therapeutics Market Drivers
 Table 13. Oligonucleotide Therapeutics Market Challenges
 Table 14. Oligonucleotide Therapeutics Market Restraints
 Table 15. Global Oligonucleotide Therapeutics Revenue by Players (2019-2024) & (US$ Million)
 Table 16. Global Oligonucleotide Therapeutics Market Share by Players (2019-2024)
 Table 17. Global Top Oligonucleotide Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oligonucleotide Therapeutics as of 2023)
 Table 18. Global Oligonucleotide Therapeutics Industry Ranking 2022 VS 2023
 Table 19. Global 5 Largest Players Market Share by Oligonucleotide Therapeutics Revenue (CR5 and HHI) & (2019-2024)
 Table 20. Global Key Players of Oligonucleotide Therapeutics, Headquarters and Area Served
 Table 21. Global Key Players of Oligonucleotide Therapeutics, Product and Application
 Table 22. Global Key Players of Oligonucleotide Therapeutics, Date of Enter into This Industry
 Table 23. Mergers & Acquisitions, Expansion Plans
 Table 24. Global Oligonucleotide Therapeutics Market Size by Type (2019-2024) & (US$ Million)
 Table 25. Global Oligonucleotide Therapeutics Revenue Market Share by Type (2019-2024)
 Table 26. Global Oligonucleotide Therapeutics Forecasted Market Size by Type (2025-2030) & (US$ Million)
 Table 27. Global Oligonucleotide Therapeutics Revenue Market Share by Type (2025-2030)
 Table 28. Global Oligonucleotide Therapeutics Market Size by Application (2019-2024) & (US$ Million)
 Table 29. Global Oligonucleotide Therapeutics Revenue Market Share by Application (2019-2024)
 Table 30. Global Oligonucleotide Therapeutics Forecasted Market Size by Application (2025-2030) & (US$ Million)
 Table 31. Global Oligonucleotide Therapeutics Revenue Market Share by Application (2025-2030)
 Table 32. North America Oligonucleotide Therapeutics Market Size by Type (2019-2024) & (US$ Million)
 Table 33. North America Oligonucleotide Therapeutics Market Size by Type (2025-2030) & (US$ Million)
 Table 34. North America Oligonucleotide Therapeutics Market Size by Application (2019-2024) & (US$ Million)
 Table 35. North America Oligonucleotide Therapeutics Market Size by Application (2025-2030) & (US$ Million)
 Table 36. North America Oligonucleotide Therapeutics Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
 Table 37. North America Oligonucleotide Therapeutics Market Size by Country (2019-2024) & (US$ Million)
 Table 38. North America Oligonucleotide Therapeutics Market Size by Country (2025-2030) & (US$ Million)
 Table 39. Europe Oligonucleotide Therapeutics Market Size by Type (2019-2024) & (US$ Million)
 Table 40. Europe Oligonucleotide Therapeutics Market Size by Type (2025-2030) & (US$ Million)
 Table 41. Europe Oligonucleotide Therapeutics Market Size by Application (2019-2024) & (US$ Million)
 Table 42. Europe Oligonucleotide Therapeutics Market Size by Application (2025-2030) & (US$ Million)
 Table 43. Europe Oligonucleotide Therapeutics Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
 Table 44. Europe Oligonucleotide Therapeutics Market Size by Country (2019-2024) & (US$ Million)
 Table 45. Europe Oligonucleotide Therapeutics Market Size by Country (2025-2030) & (US$ Million)
 Table 46. China Oligonucleotide Therapeutics Market Size by Type (2019-2024) & (US$ Million)
 Table 47. China Oligonucleotide Therapeutics Market Size by Type (2025-2030) & (US$ Million)
 Table 48. China Oligonucleotide Therapeutics Market Size by Application (2019-2024) & (US$ Million)
 Table 49. China Oligonucleotide Therapeutics Market Size by Application (2025-2030) & (US$ Million)
 Table 50. Asia Oligonucleotide Therapeutics Market Size by Type (2019-2024) & (US$ Million)
 Table 51. Asia Oligonucleotide Therapeutics Market Size by Type (2025-2030) & (US$ Million)
 Table 52. Asia Oligonucleotide Therapeutics Market Size by Application (2019-2024) & (US$ Million)
 Table 53. Asia Oligonucleotide Therapeutics Market Size by Application (2025-2030) & (US$ Million)
 Table 54. Asia Oligonucleotide Therapeutics Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
 Table 55. Asia Oligonucleotide Therapeutics Market Size by Region (2019-2024) & (US$ Million)
 Table 56. Asia Oligonucleotide Therapeutics Market Size by Region (2025-2030) & (US$ Million)
 Table 57. Middle East, Africa, and Latin America Oligonucleotide Therapeutics Market Size by Type (2019-2024) & (US$ Million)
 Table 58. Middle East, Africa, and Latin America Oligonucleotide Therapeutics Market Size by Type (2025-2030) & (US$ Million)
 Table 59. Middle East, Africa, and Latin America Oligonucleotide Therapeutics Market Size by Application (2019-2024) & (US$ Million)
 Table 60. Middle East, Africa, and Latin America Oligonucleotide Therapeutics Market Size by Application (2025-2030) & (US$ Million)
 Table 61. Middle East, Africa, and Latin America Oligonucleotide Therapeutics Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
 Table 62. Middle East, Africa, and Latin America Oligonucleotide Therapeutics Market Size by Country (2019-2024) & (US$ Million)
 Table 63. Middle East, Africa, and Latin America Oligonucleotide Therapeutics Market Size by Country (2025-2030) & (US$ Million)
 Table 64. Sarepta Therapeutics Company Details
 Table 65. Sarepta Therapeutics Business Overview
 Table 66. Sarepta Therapeutics Oligonucleotide Therapeutics Product
 Table 67. Sarepta Therapeutics Revenue in Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
 Table 68. Sarepta Therapeutics Recent Development
 Table 69. Ionis Pharmaceuticals Company Details
 Table 70. Ionis Pharmaceuticals Business Overview
 Table 71. Ionis Pharmaceuticals Oligonucleotide Therapeutics Product
 Table 72. Ionis Pharmaceuticals Revenue in Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
 Table 73. Ionis Pharmaceuticals Recent Development
 Table 74. Alnylam Company Details
 Table 75. Alnylam Business Overview
 Table 76. Alnylam Oligonucleotide Therapeutics Product
 Table 77. Alnylam Revenue in Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
 Table 78. Alnylam Recent Development
 Table 79. Biogen Company Details
 Table 80. Biogen Business Overview
 Table 81. Biogen Oligonucleotide Therapeutics Product
 Table 82. Biogen Revenue in Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
 Table 83. Biogen Recent Development
 Table 84. Nippon Shinyaku Company Details
 Table 85. Nippon Shinyaku Business Overview
 Table 86. Nippon Shinyaku Oligonucleotide Therapeutics Product
 Table 87. Nippon Shinyaku Revenue in Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
 Table 88. Nippon Shinyaku Recent Development
 Table 89. Sobi Company Details
 Table 90. Sobi Business Overview
 Table 91. Sobi Oligonucleotide Therapeutics Product
 Table 92. Sobi Revenue in Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
 Table 93. Sobi Recent Development
 Table 94. Novartis Company Details
 Table 95. Novartis Business Overview
 Table 96. Novartis Oligonucleotide Therapeutics Product
 Table 97. Novartis Revenue in Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
 Table 98. Novartis Recent Development
 Table 99. BioNTech Company Details
 Table 100. BioNTech Business Overview
 Table 101. BioNTech Oligonucleotide Therapeutics Product
 Table 102. BioNTech Revenue in Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
 Table 103. BioNTech Recent Development
 Table 104. Pfizer Company Details
 Table 105. Pfizer Business Overview
 Table 106. Pfizer Oligonucleotide Therapeutics Product
 Table 107. Pfizer Revenue in Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
 Table 108. Pfizer Recent Development
 Table 109. Moderna Therapeutics Company Details
 Table 110. Moderna Therapeutics Business Overview
 Table 111. Moderna Therapeutics Oligonucleotide Therapeutics Product
 Table 112. Moderna Therapeutics Revenue in Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
 Table 113. Moderna Therapeutics Recent Development
 Table 114. Jazz Pharmaceuticals Company Details
 Table 115. Jazz Pharmaceuticals Business Overview
 Table 116. Jazz Pharmaceuticals Oligonucleotide Therapeutics Product
 Table 117. Jazz Pharmaceuticals Revenue in Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
 Table 118. Jazz Pharmaceuticals Recent Development
 Table 119. CureVac Company Details
 Table 120. CureVac Business Overview
 Table 121. CureVac Oligonucleotide Therapeutics Product
 Table 122. CureVac Revenue in Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
 Table 123. CureVac Recent Development
 Table 124. Regulus Therapeutics Company Details
 Table 125. Regulus Therapeutics Business Overview
 Table 126. Regulus Therapeutics Oligonucleotide Therapeutics Product
 Table 127. Regulus Therapeutics Revenue in Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
 Table 128. Regulus Therapeutics Recent Development
 Table 129. ProQR Company Details
 Table 130. ProQR Business Overview
 Table 131. ProQR Oligonucleotide Therapeutics Product
 Table 132. ProQR Revenue in Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
 Table 133. ProQR Recent Development
 Table 134. Secarna Company Details
 Table 135. Secarna Business Overview
 Table 136. Secarna Oligonucleotide Therapeutics Product
 Table 137. Secarna Revenue in Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
 Table 138. Secarna Recent Development
 Table 139. MiNA Therapeutics Company Details
 Table 140. MiNA Therapeutics Business Overview
 Table 141. MiNA Therapeutics Oligonucleotide Therapeutics Product
 Table 142. MiNA Therapeutics Revenue in Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
 Table 143. MiNA Therapeutics Recent Development
 Table 144. Sylentis Company Details
 Table 145. Sylentis Business Overview
 Table 146. Sylentis Oligonucleotide Therapeutics Product
 Table 147. Sylentis Revenue in Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
 Table 148. Sylentis Recent Development
 Table 149. Arrowhead Company Details
 Table 150. Arrowhead Business Overview
 Table 151. Arrowhead Oligonucleotide Therapeutics Product
 Table 152. Arrowhead Revenue in Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
 Table 153. Arrowhead Recent Development
 Table 154. Silence Therapeutics Company Details
 Table 155. Silence Therapeutics Business Overview
 Table 156. Silence Therapeutics Oligonucleotide Therapeutics Product
 Table 157. Silence Therapeutics Revenue in Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
 Table 158. Silence Therapeutics Recent Development
 Table 159. Dicerna Company Details
 Table 160. Dicerna Business Overview
 Table 161. Dicerna Oligonucleotide Therapeutics Product
 Table 162. Dicerna Revenue in Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
 Table 163. Dicerna Recent Development
 Table 164. Research Programs/Design for This Report
 Table 165. Key Data Information from Secondary Sources
 Table 166. Key Data Information from Primary Sources


List of Figures
 Figure 1. Global Oligonucleotide Therapeutics Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
 Figure 2. Global Oligonucleotide Therapeutics Market Share by Type: 2023 VS 2030
 Figure 3. Antisense Oligonucleotides (ASO) Features
 Figure 4. siRNA Features
 Figure 5. mRNA Features
 Figure 6. Global Oligonucleotide Therapeutics Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
 Figure 7. Global Oligonucleotide Therapeutics Market Share by Application: 2023 VS 2030
 Figure 8. Neuromuscular Diseases Case Studies
 Figure 9. hATTR Case Studies
 Figure 10. COVID-19 Case Studies
 Figure 11. Other Case Studies
 Figure 12. Oligonucleotide Therapeutics Report Years Considered
 Figure 13. Global Oligonucleotide Therapeutics Market Size (US$ Million), Year-over-Year: 2019-2030
 Figure 14. Global Oligonucleotide Therapeutics Market Size, (US$ Million), 2019 VS 2023 VS 2030
 Figure 15. Global Oligonucleotide Therapeutics Market Share by Region: 2023 VS 2030
 Figure 16. Global Oligonucleotide Therapeutics Market Share by Players in 2023
 Figure 17. Global Top Oligonucleotide Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oligonucleotide Therapeutics as of 2023)
 Figure 18. The Top 10 and 5 Players Market Share by Oligonucleotide Therapeutics Revenue in 2023
 Figure 19. North America Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 20. North America Oligonucleotide Therapeutics Market Share by Type (2019-2030)
 Figure 21. North America Oligonucleotide Therapeutics Market Share by Application (2019-2030)
 Figure 22. North America Oligonucleotide Therapeutics Market Share by Country (2019-2030)
 Figure 23. United States Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 24. Canada Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 25. Europe Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 26. Europe Oligonucleotide Therapeutics Market Share by Type (2019-2030)
 Figure 27. Europe Oligonucleotide Therapeutics Market Share by Application (2019-2030)
 Figure 28. Europe Oligonucleotide Therapeutics Market Share by Country (2019-2030)
 Figure 29. Germany Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 30. France Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 31. U.K. Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 32. Italy Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 33. Russia Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 34. Nordic Countries Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 35. China Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 36. China Oligonucleotide Therapeutics Market Share by Type (2019-2030)
 Figure 37. China Oligonucleotide Therapeutics Market Share by Application (2019-2030)
 Figure 38. Asia Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 39. Asia Oligonucleotide Therapeutics Market Share by Type (2019-2030)
 Figure 40. Asia Oligonucleotide Therapeutics Market Share by Application (2019-2030)
 Figure 41. Asia Oligonucleotide Therapeutics Market Share by Region (2019-2030)
 Figure 42. Japan Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 43. South Korea Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 44. China Taiwan Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 45. Southeast Asia Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 46. India Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 47. Australia Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 48. Middle East, Africa, and Latin America Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 49. Middle East, Africa, and Latin America Oligonucleotide Therapeutics Market Share by Type (2019-2030)
 Figure 50. Middle East, Africa, and Latin America Oligonucleotide Therapeutics Market Share by Application (2019-2030)
 Figure 51. Middle East, Africa, and Latin America Oligonucleotide Therapeutics Market Share by Country (2019-2030)
 Figure 52. Brazil Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 53. Mexico Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 54. Turkey Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 55. Saudi Arabia Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 56. Israel Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 57. GCC Countries Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 58. Sarepta Therapeutics Revenue Growth Rate in Oligonucleotide Therapeutics Business (2019-2024)
 Figure 59. Ionis Pharmaceuticals Revenue Growth Rate in Oligonucleotide Therapeutics Business (2019-2024)
 Figure 60. Alnylam Revenue Growth Rate in Oligonucleotide Therapeutics Business (2019-2024)
 Figure 61. Biogen Revenue Growth Rate in Oligonucleotide Therapeutics Business (2019-2024)
 Figure 62. Nippon Shinyaku Revenue Growth Rate in Oligonucleotide Therapeutics Business (2019-2024)
 Figure 63. Sobi Revenue Growth Rate in Oligonucleotide Therapeutics Business (2019-2024)
 Figure 64. Novartis Revenue Growth Rate in Oligonucleotide Therapeutics Business (2019-2024)
 Figure 65. BioNTech Revenue Growth Rate in Oligonucleotide Therapeutics Business (2019-2024)
 Figure 66. Pfizer Revenue Growth Rate in Oligonucleotide Therapeutics Business (2019-2024)
 Figure 67. Moderna Therapeutics Revenue Growth Rate in Oligonucleotide Therapeutics Business (2019-2024)
 Figure 68. Jazz Pharmaceuticals Revenue Growth Rate in Oligonucleotide Therapeutics Business (2019-2024)
 Figure 69. CureVac Revenue Growth Rate in Oligonucleotide Therapeutics Business (2019-2024)
 Figure 70. Regulus Therapeutics Revenue Growth Rate in Oligonucleotide Therapeutics Business (2019-2024)
 Figure 71. ProQR Revenue Growth Rate in Oligonucleotide Therapeutics Business (2019-2024)
 Figure 72. Secarna Revenue Growth Rate in Oligonucleotide Therapeutics Business (2019-2024)
 Figure 73. MiNA Therapeutics Revenue Growth Rate in Oligonucleotide Therapeutics Business (2019-2024)
 Figure 74. Sylentis Revenue Growth Rate in Oligonucleotide Therapeutics Business (2019-2024)
 Figure 75. Arrowhead Revenue Growth Rate in Oligonucleotide Therapeutics Business (2019-2024)
 Figure 76. Silence Therapeutics Revenue Growth Rate in Oligonucleotide Therapeutics Business (2019-2024)
 Figure 77. Dicerna Revenue Growth Rate in Oligonucleotide Therapeutics Business (2019-2024)
 Figure 78. Bottom-up and Top-down Approaches for This Report
 Figure 79. Data Triangulation
 Figure 80. Key Executives Interviewed